BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, a formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy. In addition, the company develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health's proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. Further, the company operates HapTenix Platform, a vaccine platform based on the established immunological concept that modifies surface proteins with haptens and T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX formulation for alleviate the potentially life-threatening risk of certain food allergies triggered by exposure to peanut/tree nuts or eggs and Adiverna LLC to develop mRNA-based Rabies, Leptospirosis, Feline Infectious Peritonitis (FIV) and other mRNA-based vaccines for companion animal veterinary applications. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.…
BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
BioVaxys Technology (CNSX: BIOV) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.0700 CAD on 19 November 2026, down 74.5% over 52 weeks. Its 52-week range is 0.0300 CAD to 0.3100 CAD: the price is 77.4% below the high and 133.3% above the low.
Its market capitalisation is 2.85M CAD.
BioVaxys Technology reports return on equity of 206.0% and an operating margin of 0.0%.
Its debt exceeds its cash by 129.64K CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.